Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
23 April 2024 - 6:31AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing
company, today announced that three abstracts have been accepted
for presentation, including one oral presentation, at the 27th
Annual Meeting of the American Society of Gene and Cell Therapy
(ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and
virtually. The Company is presenting pre-clinical data to support
its development of transformative in vivo gene editing
medicines.
Editas Medicine presentations at ASGCT include:
- Oral presentation of in vivo
pre-clinical data from mouse studies using lipid nanoparticle
(LNP)-mediated delivery of an optimized guide RNA (gRNA) and
engineered AsCas12a messenger RNA (mRNA).
- Pre-clinical data demonstrating AsCas12a gRNA modifications
that enable high-potency gene editing in multiple cell types and
improve gene editing outcomes in vivo, enabling the development of
in vivo gene editing medicines.
- Research on identifying potent large serine recombinases (LSRs)
as a foundation to develop novel in vivo gene editing technologies
for whole gene knock-in, expanding potential in vivo gene editing
targets for developing medicines.
“Editas Medicine is making strong progress towards the clinic
with our technology optimization to develop transformative in vivo
medicines for people living with serious diseases,” said Linda C.
Burkly, Ph.D., Executive Vice President and Chief Scientific
Officer, Editas Medicine. “We look forward to sharing compelling
data at ASGCT next month, including data demonstrating the delivery
of AsCas12a mRNA using LNPs in vivo and guide RNA modifications to
increase potency. These in vivo data are an important step towards
confirming in vivo proof of concept by the end of the year.”
The complete list of Editas Medicine presentations is below.
Abstracts can be accessed on the ASGCT website, and the
presentations will be posted on the Editas Medicine website during
the conference.
Oral Presentation:Title:
LNP-Based Delivery of CRISPR/Cas12a for the Potential Treatment of
Myocilin-Associated GlaucomaSession Date and
Time: Friday, May 10, 2024, 3:45 – 5:30 p.m. ET
Presentation Time: 4:00 - 4:15 p.m.Session
title: Advancements in Technologies for In Vivo Gene
Therapies Room: Room
324-326 Final Abstract Number: 276
Poster Presentations:Title:
Chemically Modified AsCas12a Guide RNAs Improve Lipid
Nanoparticle-Mediated In Vivo Gene Editing in Different
TissuesSession Date and Time: Thursday, May 9,
2024, 12:00 p.m. ET Session Title: Thursday
Posters: Gene Disruption and ExcisionPresentation
Room: Exhibit HallFinal Abstract
Number: 1182
Title: Metagenomic Discovery and Screening of
Novel Recombinase Proteins for Targeted IntegrationSession
Date and Time: Friday, May 10, 2024, 12:00 p.m. ET
Session Title: Friday Posters: Targeted Gene
Insertion Presentation Room: Exhibit
HallFinal Abstract Number: 1681
About Editas MedicineAs a
clinical-stage gene editing company, Editas Medicine is focused on
translating the power and potential of the CRISPR/Cas12a and
CRISPR/Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute’s Cas12a patent estate and Broad
Institute and Harvard University’s Cas9 patent estates for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Forward-Looking Statements This press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements in this press release include statements regarding the
initiation, timing, progress and results of the Company’s
preclinical studies and its research and development programs, and
the timing for the Company’s receipt and presentation of data from
its preclinical studies, including confirming in
vivo proof-of-concept by the end of 2024. The Company may
not actually achieve the plans, intentions, or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various important factors, including
uncertainties inherent in the initiation and completion of
pre-clinical studies and availability and timing of results from
pre-clinical studies. These and other risks are described in
greater detail under the caption “Risk Factors” included in the
Company’s most recent Annual Report on Form 10-K, which is on file
with the Securities and Exchange Commission, as updated by the
Company’s subsequent filings with the Securities and Exchange
Commission, and in other filings that the Company may make with the
Securities and Exchange Commission in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and the Company expressly disclaims any
obligation to update any forward-looking statements, whether
because of new information, future events or otherwise.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2024 to Jun 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jun 2023 to Jun 2024